← Eichor
Study identifier: NCT06994949 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Assessing CSF Flow Dynamics in Pediatric Hemorrhagic Hydrocephalus

Condition: Post-hemorrhagic Hydrocephalus (PHH)  ·  Sponsor: Eva Sevick

PhasePhase 1
Planned participants20
Who can joinAll sexes, N/A to 6 Months
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and efficacy of ventricular microdosing of indocyanine green (ICG) in order to assess cerebrospinal fluid (CSF) ventricular dynamics and extracranial CSF outflow using fluorescent Cap-based Transcranial Optical Tomography (fCTOT) and Near-InfraRed Fluorescent (NIRF) imaging and to evaluate inflammation markers of the CSF and to correlate with CSF ventricular dynamics, extracranial outflow into the lymphatics, ventriculomegaly, and patient's clinical outcome in order to understand how inflammation may impact that status of extracranial outflow.

This description comes directly from the study's public registry record.

Talk to the study team

Manish Shah, MD  ·  (713) 500-7370  ·  Manish.N.Shah@uth.tmc.edu

Fred C Velasquez  ·  713-500-3645  ·  Fred.Christian.Velasquez@uth.tmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas Health Science Center at HoustonHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06994949